EMA

PTC Therapeutics appoints Zeldis to board of directors

Thursday, October 4, 2012 12:14 PM

PTC Therapeutics, a biopharmaceutical company based in South Plainfield, N.J., has appointed Jerome B. Zeldis, M.D., Ph.D., to the company's board of directors.

More... »

Albemarle expands South Haven API production site

Tuesday, July 10, 2012 11:19 AM

Albemarle, a global developer, manufacturer and marketer of highly engineered specialty chemicals, has begun upgraded and expanded its FDA-registered multi-product cGMP active pharmaceutical ingredient (API) manufacturing facility in South Haven, Mich.

More... »

BioTime and LifeMap to acquire XenneX

Friday, April 20, 2012 02:55 PM

BioTime, a biotech based in Alameda, Calif., and its wholly owned subsidiary LifeMap Sciences have signed a definitive agreement to acquire XenneX through a merger of XenneX into LifeMap Sciences. The acquisition is expected to close within thirty days.

More... »

HemaQuest raises $13 million for phase IIb study of sickle cell disease

Monday, March 12, 2012 03:49 PM

HemaQuest Pharmaceuticals, a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, has closed a $13 million extension of its Series B financing.

More... »

Researchers look to disease-modifying therapy to ward off, possibly prevent Alzheimer’s disease

Monday, December 19, 2011 10:25 AM

Just as statins help lower high cholesterol levels to reduce the risk of heart attacks, researchers are seeking a comparable approach for people with large amounts of beta amyloid, an abnormal protein in the brain commonly found in Alzheimer’s disease patients. Medicines would clear those proteins before any signs of memory loss or other early symptoms of Alzheimer’s appear. 

More... »

Icon boosts its presence in Asia with acquisition of Chinese CRO BeijingWits Medical Consulting

Monday, December 19, 2011 10:13 AM

Now that many mid-tier CROs have been acquired by either equity investment firms or other CROs and the trend has slowed, a new form of consolidation is emerging. Robust CROs are rounding out their offerings with small but strategic acquisitions to make them bigger, stronger and more complete. The ultimate goal: to continue winning lucrative strategic outsourcing agreements from sponsors.  

More... »

Curemark's phase III autism trial shows positive results

Wednesday, December 7, 2011 10:08 AM

Curemark has reported its phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. The trial compared CM-AT to placebo in children with autism aged 3-8. Top line results demonstrate a statistically significant effect of CM-AT over placebo on both core and non-core symptoms of autism.

More... »

Report: Clinical trials approved in Russia on course in third quarter

Monday, November 7, 2011 11:26 AM

The number of new studies approved in Russia during the third quarter of 2011 reached last year’s level, with the Ministry of Health and Social Development of the Russian Federation (MoH) approving 132 new clinical trials of all types, including local and bioequivalence studies, according to Synergy Research Group (SynRG), a Russia-based CRO. That’s only two trials below the number approved in the year-ago quarter.

More... »

Quintiles fills in service offerings with acquisitions

Monday, November 7, 2011 08:00 AM

Quintiles has been on an acquisitions spree. 

More... »

EU Clinical Trials Register to be available on WHO’s ICTRP portal

Thursday, September 22, 2011 02:13 PM

The European Union Clinical Trials Register (EU-CTR) has been recognized as one of the primary registries for the World Health Organization’s (WHO) International Clinical Trials Registry Platform (ICTRP), according to PharmaTimes.

More... »